S 38093

Drug Profile

S 38093

Alternative Names: S38093

Latest Information Update: 23 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Servier
  • Class Antidementias
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 23 Jul 2015 Phase-II development is ongoing in the United Kingdom
  • 01 Jan 2015 Servier completes a phase II trial in Alzheimer's disease (Combination therapy, In adults, In the elderly) in Austria, Finland, Italy, Germany, Poland, Portugal, Spain, Sweden, Slovakia and United Kingdom (EudraCT2011-005862-40)
  • 01 Apr 2014 Servier completes a phase II trial in Alzheimer's disease in Australia, Brazil, Bulgaria, Chile, Czech Republic, France, Germany, Hungary , Mexico, Portugal, Romania, Russia and South Africa (EudraCT2010-024626-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top